Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 18, 2023 08:00 ET | Source: Ardelyx, Inc.

Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)

WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
April 13, 2023 16:05 ET | Source: Ardelyx, Inc.

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
April 12, 2023 16:05 ET | Source: Ardelyx, Inc.

Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings

Three posters support the important role that XPHOZAH, a novel phosphate absorption inhibitor, could potentially play in the treatment of hyperphosphatemia XPHOZAH consistently lowered serum...
March 02, 2023 16:02 ET | Source: Ardelyx, Inc.

Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Continued successful launch of IBSRELA, ending FY 2022 with $15.6 million in net product sales Resubmission of XPHOZAH New Drug Application expected in early Q2 2023 Company ends Q4 with...
February 28, 2023 08:00 ET | Source: Ardelyx, Inc.

Ardelyx Publishes First Environmental, Social and Governance (ESG) Report

WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
February 27, 2023 08:15 ET | Source: Ardelyx, Inc.

Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference

WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
February 23, 2023 08:00 ET | Source: Ardelyx, Inc.

Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023

WALTHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...